Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics | $16.72 | -$7.73 | -31.62% | 633.6K | $2.4B | $10.42$138.81 |
| ICHR | Ichor | $16.04 | -$6.88 | -30.02% | 2.1M | $786.8M | $13.12$36.48 |
| ARTL | Artelo Biosciences | $2.12 | -$0.88 | -29.35% | 6.1M | $3.4M | $2.08$28.60 |
| JELD | Jeld-wen | $3.02 | -$1.18 | -28.09% | 6.1M | $358.7M | $2.31$11.66 |
| FLYE | Fly-E Group | $7.40 | -$2.60 | -26.00% | 80.5K | $189.0M | $6.85$166.00 |
| ESLA | Estrella Immunopharma | $2.29 | -$0.76 | -24.92% | 753.5K | $113.1M | $0.70$3.15 |
| NOMA | Nomadar | $8.65 | -$2.85 | -24.78% | 68.4K | - | $2.00$57.70 |
| CJET | Chijet Motor | $2.91 | -$0.92 | -23.98% | 233.9K | $350.4M | $2.77$299.00 |
| FORD | Forward Industries | $10.69 | -$3.29 | -23.53% | 2.2M | $1.2B | $3.32$46.00 |
| SOUX | Tidal Trust II - Defiance Daily Target 2x Long Soun ETF | $34.87 | -$9.95 | -22.20% | 343.4K | - | $19.16$78.10 |
Related Articles
Featured Article
Is This Stock a Buy After Soaring by 20% in 1 Day?
Prosper Junior Bakiny|Jul 24, 2025
With Its Kpler Deal on the Rocks, Can Spire Stock Survive?
Rich Smith|Mar 16, 2025
If you pay close enough attention to conference calls, you just might find a stock that can double -- like Spire Global.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Alex Carchidi|Jul 6, 2024
One key issue remains unresolved, and it could be a significant one.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
David Jagielski|Jul 4, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|Jul 3, 2024
Let's look beyond the biotech's performance this year.
1 Top Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|May 1, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Alex Carchidi|Mar 13, 2024
The threat is still emerging, but it could be significant.
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
Alex Carchidi|Mar 4, 2024
The upcoming regulatory decision on its latest drug could be big.
Is It Too Late to Buy Sarepta Therapeutics Stock?
Prosper Junior Bakiny|Feb 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.
2 Magnificent Growth Stocks to Buy With $500
Prosper Junior Bakiny|Feb 15, 2024
No need to break the bank to invest in promising stocks.
